Drug Patents owned by Eyepoint Pharms
1. List of Dexycu Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7560120 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Sep, 2022
(5 months ago) | |
| US6960346 | EYEPOINT PHARMS | Vehicles for delivery of biologically active substances |
Jul, 2023
(4 months from now) | |
| US10799642 | EYEPOINT PHARMS | Dose guides for injection syringe |
May, 2032
(9 years from now) | |
| US10028965 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
| US10159683 | EYEPOINT PHARMS | Use of sustained release dexamethasone in post-cataract surgery inflammation |
May, 2034
(11 years from now) | |
| US10022502 | EYEPOINT PHARMS | Dose guides for injection syringe |
Jun, 2034
(11 years from now) | |
| US11097061 | EYEPOINT PHARMS | Systems, kits and methods for loading and delivering a small volume dose from a syringe |
Jun, 2039
(16 years from now) | |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 09 February, 2018
Treatment: Treatment of postoperative inflammation; A method of loading medication into a syringe and delivering the medication to a treatment site
Dosage: SUSPENSION;INTRAOCULAR
2. List of Yutiq drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8871241 | EYEPOINT PHARMS | Injectable sustained release delivery devices |
Aug, 2027
(4 years from now) | |
| US7998108 | EYEPOINT PHARMS | Injector apparatus and method of use |
Jan, 2028
(4 years from now) | |
Drugs and Companies using FLUOCINOLONE ACETONIDE ingredient
Market Authorisation Date: 12 October, 2018
Treatment: A method of injecting an implant
Dosage: IMPLANT;INTRAVITREAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic